Abstract
Twenty volunteers were trained to discriminate between 75 mg tripelennamine (TP) and placebo. During the first four sessions, the drugs were identified prior to ingestion by letter code. During the next six sessions, the procedure was the same except the capsules were not identified. At the end of the 3-h session, participants indicated which capsule they believed they received using the letter codes. When correct, they received a monetary bonus. If they were correct on five sessions, they entered the third phase which had ten additional training and 12 test sessions. During tests, participants received capsules that contained other drugs, including diphenhydramine (50 and 75 mg), chlorpheniramine (4 and 6 mg), diazepam (5 and 10 mg),d-amphetamine (5 and 10 mg), as well as tripelennamine (25, 50 and 75 mg) and placebo. Thirteen participants learned the discrimination and nine entered the third phase. Except for placebo, most participants identified the test compounds as TP and labeled them as sedatives. TP produced significant changes on several subjective and physiological measures. The test compounds produced varied effects which were neither clearly dose-related nor related to the identification as TP or placebo. These results indicate that tripelennamine can function as a discriminative stimulus, but with little evidence of pharmacological specificity.
Similar content being viewed by others
References
Barnett A, Iorio LC, Kreutner W, Tozzi S, Ahn HS, Gulbenkian A (1984) Evaluation of the CNS properties of SCH29851, a potential non-sedating antihistamine. Agents Actions 14:590–597
Bergman J, Spealman RD (1986) Some behavioral effects of histamine H1 antagonists in squirrel monkeys. J Pharmacol Exp Ther 239:104–110
Bickel WK, Bigelow GE, Preston KL, Liebson IA (1989) Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect. J Pharmacol Exp Ther 251:1053–1063
Carruthers SG, Shoeman DW, Hignite CE, Azarnoff DL (1978) Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther 23:375–382
Chait LD, Uhlenhuth EH, Johanson CE (1984) An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology 82:272–274
Chait LD, Uhlenhuth EH, Johanson CE (1985) The discriminative stimulus and subjective effects ofd-amphetamine in humans. Psychopharmacology 86:307–312
Chait LD, Uhlenhuth EH, Johanson CE (1986a) The discriminative stimulus and subjective effects ofd-amphetamine, phenmetrazine and fenfluramine in humans. Psychopharmacology 89:301–306
Chait LD, Uhlenhuth EH, Johanson CE (1986b) The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol, andd-amphetamine in humans. Pharmacol Biochem Behav 24:1665–1672
Chait LD, Uhlenhuth EH, Johanson CE (1989) Individual differences in the discriminative stimulus effects ofd-amphetamine in humans. Drug Dev Res 16:451–460
Colpaert FC, Balster RL (eds) (1988) Transduction mechanisms of drug stimuli. Springer, Berlin
Evans SM, Johanson CE (1989) Discriminative stimulus properties of histamine H1-antagonists in animals trained to discriminated-amphetamine or pentobarbital. J Pharmacol Exp Ther 250:779–787
Evans SM, Zacny JP, Woolverton WL, Johanson CE (1991) The discriminative stimulus effects of histamine H1-antagonists in pigeons. Behav Pharmacol 2:447–460
Haertzen CA (1966) Development of scales based on patterns of drug effects using the Addiction Research Center Inventory (ARCI). Psych Rep 18:163–194
Johanson CE (1991a) The discriminative stimulus effects of diazepam in humans. J Pharmacol Exp Ther 257:634–643
Johanson CE (1991b) Further studies of the discriminative stimulus effects of diazepam in humans. Behav Pharmacol 2:357–367
Johanson CE (1993) The discriminative stimulus effects of buspirone in humans. Exp Clin Psychopharmacol 1:173–187
Kamien JB, Bickel WK, Hughes JR, Higgins ST, Smith B (1993) Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology 111:259–270
Kamien JB, Bickel WK, Oliveto AH, Higgins ST, Hughes JR, Richards AT, Badger, GJ (1995) Placebo-effects contribute to differences in the acquisition of drug discrimination by humans: a retrospective analysis. Behav Pharmacol 6:187–194
Kulshrestha VK, Gupta PP, Turner P, Wadsworth J (1978) Some clinical pharmacological studies with terfenadine, a new antihistamine drug. Br J Clin Pharmacol 6:25–29
Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective and behavioral effects of amphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258
McNair DM, Lorr M, Droppleman LF (1971) Manual for the profile of mood states. Educational and Industrial Testing Service, San Diego
Melville KI (1973) Antihistamine drugs. In: Peters G, Schachter M (eds) International encyclopedia of pharmacology and therapeutics, section 74: histamine and antihistamines. Pergamon Press, Oxford, pp 127–171
Preston KL, Bigelow GE, Bickel WK, Liebson IA (1987) Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharmacol Exp Ther 243:1002–1009
Preston KL, Bigelow GE, Bickel WK, Liebson IA (1989) Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250:184–196
Schuster CR, Johanson CE (1988) Relationship between the discriminative stimulus properties and subjective effects of drugs. In: Colpaert FC, Balster RL (eds) Transduction mechanisms of drug stimuli. Springer (Psychopharmacology Supplementum Series), Berlin, pp 161–175
Stern KN, Chait LD, Johanson CE (1989) Reinforcing and subjective effects of oral tripelennamine in normal volunteers. Behav Pharmacol 1:161–167
Stolerman IP, Rasul F, Shine PJ (1989) Trends in drug discrimination research analysed with a cross-indexed bibliography. Psychopharmacology 98:1–19
Stolerman IP, Shine PJ (1985) Trends in drug discrimination research analysed with a cross-indexed bibliography, 1982–1983. Psychopharmacology 86:1–11
Young AM (1991) Discriminative stimulus profiles of psychoactive drugs. In: Mello NK (ed) Advances in substance abuse: behavioral and biological research, vol 4. Jessica Kingsley Publishers, London, pp 139–203
Author information
Authors and Affiliations
Additional information
The opinions expressed by the authors are not necessarily those of the United States Government. Portions of the data were presented as a poster at the 1993 annual meeting of the College on Problems of Drug Dependence, which was published as an abstract (Evans S, Henningfield J, Johanson CE (1994) Discriminative stimulus effects of tripelennamine in humans. In Problems of Drug Dependence 1993: Proceedings of the 55th Annual Scientific Meeting. Harris LS (ed) National Institute on Drug Abuse Research Monograph Series 141:396)
Rights and permissions
About this article
Cite this article
Johanson, C.E., Evans, S. & Henningfield, J. The discriminative stimulus effects of tripelennamine in humans. Psychopharmacology 126, 140–146 (1996). https://doi.org/10.1007/BF02246349
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246349